Chapter 1: A General Framework for Regulatory Intelligence in Medical Product Research and Development
8 Regulatory Affairs Professionals Society
can take many forms, and you should establish a structured
approach to disseminating your RI alerts. These updates could
be written via email or newsletters, provided verbally during
team meetings, or taken through other approaches. For teams
with digital knowledge bases and databases, updating these
systems can be a vital way to communicate intelligence sig‑
nals to colleagues. Regularly refreshing these systems with the
latest information ensures that your stakeholders have access
to current and reliable data.
When communicating updates from your continuous
monitoring program, you will typically need to summa‑
rize them by highlighting the following information: a
description of the news item, a summary of any changes
from previous version(s), and an assessment of the potential
impact to the organization. The level of impact assessment
will vary depending on the structure of your team and their
responsibilities.
For request-driven updates (sometimes called ad hoc
requests), the content and format of communication should
meet the needs of the person or team requesting the informa‑
tion. If they need to present the findings in a meeting, then
slides may be appropriate. In other cases, an email or nar‑
rative document may be better. If the findings are the result
of data analysis, then the raw data and explanation of the
data analysis methodologies should also be included in the
communication.
Part of communicating the alerts is knowing who needs
to receive information based on the topics and areas of inter‑
est. It is not a trivial task to keep track of distribution lists for
your team, and part of establishing a structured approach to
disseminating information should include maintaining and
using RI distribution lists. Wherever possible, you should
provide stakeholders with mechanisms to manage their own
subscriptions to these lists, rather than trying to manually
maintain the lists yourself. Allowing stakeholders to manage
their own subscriptions fosters personal responsibility for RI
engagement, ensures lists are updated based on stakeholders’
current role, and allows RI staff to focus on strategic activities
rather than administrative processes.
Evaluation Processes. Evaluation is where information
transforms into insights. Each regulatory affairs function
evaluates new information through the lens of its own
responsibilities. However, the underlying principles remain
the same: assess what has changed, determine its meaning in
terms of impact (or potential impact), and decide what, if any,
action is required. This shared structure promotes consistency
and quality in decision making while allowing for disci‑
pline-specific interpretation.
For regulatory strategy teams, evaluation tends to focus
on how new guidance, precedent, or agency actions may
influence product development plans or agency interactions.
A newly issued EMA guidance document on decentralized
trials, for example, may prompt a structured review of how
ongoing clinical protocols align with the new expectations.
Teams assess the relevance to each development program,
the feasibility of adapting new practices, and the potential for
benefits or risks to regulatory strategies.
In regulatory labeling, evaluations may concentrate on
the impact of new labeling standards, precedent, safety infor‑
mation, or class-wide changes. A team can compare a new
FDA safety labeling guideline with their product’s current
label or target product profile (TPP), identifying discrepan‑
cies and preparing recommendations for updates. Evaluations
here emphasize clarity, compliance, and consistency with
emerging patterns.
For regulatory CMC functions, evaluations may center
on how changes to manufacturing standards or quality expec‑
tations could affect ongoing or planned submissions. When
the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH)5
revises a Q-series guideline,6 for example, CMC teams typi‑
cally conduct a gap assessment against internal procedures to
determine whether any control strategies, specifications, or
validation data packages require updates.
Regulatory policy and pharmacovigilance teams conduct
broader, often cross-functional evaluations. Policy specialists
may analyze a new agency framework for digital health tech‑
nologies, synthesizing insights from subject matter experts
to inform an organization’s position or public comments.
Pharmacovigilance professionals may assess new signal
detection requirements to determine whether internal safety
monitoring systems are still compliant.
In all cases, effective evaluation depends on traceability.
You should document how information was interpreted,
who was consulted, and what conclusions were reached. This
recordkeeping supports transparency, accountability, and
reuse of insights in future projects. Maintaining a structured,
flexible, and repeatable approach to RI evaluations enables
organizations to respond quickly to the evolving regulatory
environment.
Action Processes. Action is the defining characteristic
of effective RI programs. Without it, intelligence remains
theoretical and disconnected from the organization’s goals.
The types of actions taken depend on the regulatory affairs
team performing them. However, all are aimed at improving
decision quality, compliance, and ultimately, patient outcomes.
After completing evaluations, teams may implement
operational or quality system changes. For example, a GxP
quality group may update standard operating procedures fol‑
lowing the evaluation of new agency inspection trends. These
updates would ensure that the organization’s good practices
align with the latest expectations and minimize the risks of
inspection findings.
Product-focused teams often revise strategies, labels,
target product labeling (TPL), or TPPs based on regulatory
insights developed from the evaluation of new precedents
and product-related actions taken by health authorities. A
regulatory strategy team might modify a clinical develop‑
ment plan to include an additional end point highlighted in a
recent approval. In contrast, a labeling team may incorporate
updates to contraindications or harmonized terminology as a
result of RI programs.
Other actions involve policy and advocacy activities.
When new guidance or draft legislation appears, policy teams
8 Regulatory Affairs Professionals Society
can take many forms, and you should establish a structured
approach to disseminating your RI alerts. These updates could
be written via email or newsletters, provided verbally during
team meetings, or taken through other approaches. For teams
with digital knowledge bases and databases, updating these
systems can be a vital way to communicate intelligence sig‑
nals to colleagues. Regularly refreshing these systems with the
latest information ensures that your stakeholders have access
to current and reliable data.
When communicating updates from your continuous
monitoring program, you will typically need to summa‑
rize them by highlighting the following information: a
description of the news item, a summary of any changes
from previous version(s), and an assessment of the potential
impact to the organization. The level of impact assessment
will vary depending on the structure of your team and their
responsibilities.
For request-driven updates (sometimes called ad hoc
requests), the content and format of communication should
meet the needs of the person or team requesting the informa‑
tion. If they need to present the findings in a meeting, then
slides may be appropriate. In other cases, an email or nar‑
rative document may be better. If the findings are the result
of data analysis, then the raw data and explanation of the
data analysis methodologies should also be included in the
communication.
Part of communicating the alerts is knowing who needs
to receive information based on the topics and areas of inter‑
est. It is not a trivial task to keep track of distribution lists for
your team, and part of establishing a structured approach to
disseminating information should include maintaining and
using RI distribution lists. Wherever possible, you should
provide stakeholders with mechanisms to manage their own
subscriptions to these lists, rather than trying to manually
maintain the lists yourself. Allowing stakeholders to manage
their own subscriptions fosters personal responsibility for RI
engagement, ensures lists are updated based on stakeholders’
current role, and allows RI staff to focus on strategic activities
rather than administrative processes.
Evaluation Processes. Evaluation is where information
transforms into insights. Each regulatory affairs function
evaluates new information through the lens of its own
responsibilities. However, the underlying principles remain
the same: assess what has changed, determine its meaning in
terms of impact (or potential impact), and decide what, if any,
action is required. This shared structure promotes consistency
and quality in decision making while allowing for disci‑
pline-specific interpretation.
For regulatory strategy teams, evaluation tends to focus
on how new guidance, precedent, or agency actions may
influence product development plans or agency interactions.
A newly issued EMA guidance document on decentralized
trials, for example, may prompt a structured review of how
ongoing clinical protocols align with the new expectations.
Teams assess the relevance to each development program,
the feasibility of adapting new practices, and the potential for
benefits or risks to regulatory strategies.
In regulatory labeling, evaluations may concentrate on
the impact of new labeling standards, precedent, safety infor‑
mation, or class-wide changes. A team can compare a new
FDA safety labeling guideline with their product’s current
label or target product profile (TPP), identifying discrepan‑
cies and preparing recommendations for updates. Evaluations
here emphasize clarity, compliance, and consistency with
emerging patterns.
For regulatory CMC functions, evaluations may center
on how changes to manufacturing standards or quality expec‑
tations could affect ongoing or planned submissions. When
the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH)5
revises a Q-series guideline,6 for example, CMC teams typi‑
cally conduct a gap assessment against internal procedures to
determine whether any control strategies, specifications, or
validation data packages require updates.
Regulatory policy and pharmacovigilance teams conduct
broader, often cross-functional evaluations. Policy specialists
may analyze a new agency framework for digital health tech‑
nologies, synthesizing insights from subject matter experts
to inform an organization’s position or public comments.
Pharmacovigilance professionals may assess new signal
detection requirements to determine whether internal safety
monitoring systems are still compliant.
In all cases, effective evaluation depends on traceability.
You should document how information was interpreted,
who was consulted, and what conclusions were reached. This
recordkeeping supports transparency, accountability, and
reuse of insights in future projects. Maintaining a structured,
flexible, and repeatable approach to RI evaluations enables
organizations to respond quickly to the evolving regulatory
environment.
Action Processes. Action is the defining characteristic
of effective RI programs. Without it, intelligence remains
theoretical and disconnected from the organization’s goals.
The types of actions taken depend on the regulatory affairs
team performing them. However, all are aimed at improving
decision quality, compliance, and ultimately, patient outcomes.
After completing evaluations, teams may implement
operational or quality system changes. For example, a GxP
quality group may update standard operating procedures fol‑
lowing the evaluation of new agency inspection trends. These
updates would ensure that the organization’s good practices
align with the latest expectations and minimize the risks of
inspection findings.
Product-focused teams often revise strategies, labels,
target product labeling (TPL), or TPPs based on regulatory
insights developed from the evaluation of new precedents
and product-related actions taken by health authorities. A
regulatory strategy team might modify a clinical develop‑
ment plan to include an additional end point highlighted in a
recent approval. In contrast, a labeling team may incorporate
updates to contraindications or harmonized terminology as a
result of RI programs.
Other actions involve policy and advocacy activities.
When new guidance or draft legislation appears, policy teams